Compare RCKT & GBAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCKT | GBAB |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.2M | 412.4M |
| IPO Year | N/A | 2010 |
| Metric | RCKT | GBAB |
|---|---|---|
| Price | $3.65 | $14.72 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $29.73 | N/A |
| AVG Volume (30 Days) | ★ 4.2M | 99.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $69.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.19 | $13.93 |
| 52 Week High | $8.26 | $15.94 |
| Indicator | RCKT | GBAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 52.69 |
| Support Level | $2.99 | $13.93 |
| Resistance Level | $4.08 | $15.43 |
| Average True Range (ATR) | 0.32 | 0.22 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 17.83 | 97.53 |
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.